# OnCo record nci-da-epoch-r-myc-burkitt (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nci-da-epoch-r-myc-burkitt/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nci-da-epoch-r-myc-burkitt", "NCT01092182" ;
  schema:name "NCI dose-adjusted EPOCH-R in Burkitt and MYC-rearranged large B-cell lymphoma"@en ;
  schema:alternateName "DA-EPOCH-R in MYC-rearranged lymphoma"@en, "Dunleavy 2018"@en ;
  schema:description "A single-arm study gave an intensive infusional chemotherapy to people with aggressive B-cell lymphoma carrying a MYC rearrangement, including double-hit disease, and about seven in ten were alive and free of events four years later."@en ;
  schema:url <https://onco.cc/trials/nci-da-epoch-r-myc-burkitt/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01092182>, <https://doi.org/10.1016/S2352-3026(18)30177-7> ;
  onco:status "positive" ;
  onco:tag "lymphoma-evidence-entities" ;
  onco:phase "2" ;
  schema:startDate "2010-03-25" ;
  onco:cancers <https://onco.cc/cancers/high-grade-b-cell-lymphoma-myc-bcl2/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/burkitt-lymphoma/>, <https://onco.cc/cancers/plasmablastic-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/chemotherapy/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:targets <https://onco.cc/targets/myc-gene/>, <https://onco.cc/targets/bcl2/> ;
  onco:drugs <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/doxorubicin/> ;
  onco:institutions <https://onco.cc/institutions/nci/> ;
  onco:terms <https://onco.cc/terms/double-hit-lymphoma/>, <https://onco.cc/terms/lymphoma-tx-cns-prophylaxis/>, <https://onco.cc/terms/lymphoma-tx-regimen-alphabet/> ;
  onco:trials <https://onco.cc/trials/calgb-50303/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-da-epoch-r-myc-rearranged-lymphoma-lancet-haematol-2018/> .